Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06441825
Other study ID # MPGv1.0
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date May 2, 2024
Est. completion date October 31, 2025

Study information

Verified date May 2024
Source Heinrich-Heine University, Duesseldorf
Contact Marc Pawlitzki, PD Dr. med.
Phone +49211 8117887
Email neuro-trials@med.uni-duesseldorf.de
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This observational study seeks to investigate the underlying processes of myasthenia gravis by employing multimodal monitoring techniques. By integrating digital biomarkers alongside clinical monitoring, we aim to enhance the detection of disease activity and establish correlations between digital measures, clinical scores and various questionnaires including sores on quality of life, sleep quality or activities of daily living. Primarily including patients treated with newly approved drugs, it aims at improving and monitoring the efficacy and safety of treatment and allowing a more individualized treatment.


Description:

Myasthenia Gravis (MG) is a chronic autoimmune disease characterized by muscle weakness and fatigue due to defective transmission at the neuromuscular junction. Typically, symptomatic assessments occur during clinical encounters, either as part of routine treatment assessments or in acute situations such as myasthenic crises. However, for a comprehensive understanding of mechanisms in MG and disease activity, continuous monitoring is essential. Utilization of digital biomarkers derived from wearable devices offers unprecedented insights into diseases like MG and allows us to establish correlations between digital measures, clinical scores such as the QMG scale and MGC, as well as various questionnaires addressing sleep quality, quality of life or activities of daily living. Data recorded by the used wearables (Withings Scanwatch 2) cover various parameters including activity-related data (step count, minutes in certain intensity levels), basic cardiovascular measurements such as heart rate, and sleep-related data (total time asleep, sleep quality, etc.). Prospectively, this study aims at improving patient care by gaining a deeper insight into Myasthenia Gravis and its dynamic disease activity while concurrently monitoring the efficacy and safety of treatments, particularly of the newly approved drugs for MG. In the future, wearables might hold the potential to improve treatment processes and optimize therapeutic approaches. For instance, digital biomarkers could serve as early warning signs for phenomena like heightened disease activity or end-of-dose phenomena, paving the way for personalized treatment strategies tailored to individual patient needs.


Recruitment information / eligibility

Status Recruiting
Enrollment 20
Est. completion date October 31, 2025
Est. primary completion date October 31, 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility - Formal diagnosis of generalized Myasthenia Gravis, with at least one of the following criteria: - Response to oral or intravenous administration of an acetylcholinesterase inhibitor - Evidence of pathological decrement/ elevated jitter - Evidence of Myasthenia Gravis-typical antibody (AChR, LRP4, MuSK, Titin) OR other diagnosed Myasthenic Syndrome - Age = 18 - Usage of Smartphone with Android 8.1 (or higher) or IOS12.3 (or higher) - Able to provide informed consent, based on investigator´s judgment Exclusion Criteria: Patients who meet any of the following criteria will be excluded from participation: - Unable or unwilling to give informed consent - Unable or unwilling to use the smartphone app - Any significant comorbidity that might potentially interfere with the ability to successfully participate in the study, based on investigator´s judgment - Patient with exclusively ocular symptoms (ocular myasthenia gravis)

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Increased multimodal observation including digital monitoring
Digital monitoring combined with repeated clinical assessments and retrospective analysis of serological markers

Locations

Country Name City State
Germany Heinrich-Heine University, Duesseldorf Duesseldorf

Sponsors (1)

Lead Sponsor Collaborator
Heinrich-Heine University, Duesseldorf

Country where clinical trial is conducted

Germany, 

Outcome

Type Measure Description Time frame Safety issue
Primary QMG: Quantitative Myasthenia Gravis Scale The QMG-Score is a clinical tool to assess the severity of symptoms in MG. It evaluates muscle strength and function in specific muscle groups (ocular, oral, facial, neck and limb muscles), grip strength and vital capacity. It ranges from 0 to 39, with higher scores indicating an increased symptom load. 6 months, monthly
Primary MGC: Myasthenia Gravis Composite The MGC is a clinical tool to evaluate the severity and progression of MG. It ranges from 0 to 50, with higher scores indicating a higher severity of MG. Baseline, after 3 and 6 months
Primary MGFA-PIS: Myasthenia Gravis Post intervention status The MGFA-PIS is a scoring system used to assess the status of patients with MG. It divides MG presentations into different classes, classifying outcome measures and treatment effectiveness. It has 8 classes; Minimal Manifestation can be further described within four dimensions. Baseline, after 3 and 6 months
Primary MG-ADL: Myasthenia Gravis Activities of Daily Living The MG-ADL is a tool used to assess the functional status of patients with MG in their daily activities. It consists of questions related to various activities of daily living such as speaking, chewing, swallowing, walking etc. It ranges from 0 to 24, with higher scores indicating a greater impairment in daily life. Baseline, after 3 and 6 months
Primary MG-QoL15: Myasthenia Gravis Quality of Life-15 The MG-QoL assesses the quality of life in patients with MG, covering various aspects of daily life such as physical functioning, social interactions, emotional well-being and overall satisfaction with life.
It ranges from 0 to 60, with higher scores indicating a greater impact of MG on life quality.
Baseline, after 3 and 6 months
Secondary WHOQoL-BREF: World Health Organization Quality of Life Questionnaire Brief Version The WHOQOL-BREF questionnaire measures quality of life across 4 domains: Physical health, psychological health, social relationships and environment. It also includes one question on overall QOL and one on general health. The WHOQOL-BREF scores correlate highly (.89 or above) with WHOQOL-100 scores, and demonstrate good discriminant validity, content validity, internal consistency and test-retest reliability. The four WHOQOL-BREF domain scores will be used as main outcome measure. The measure is calculated by summing the point values for the questions corresponding to each domain and then transforming the scores to a 0-100 point interval, with higher scores corresponding to greater QOL. Baseline, after 3 and 6 months
Secondary HADSD: Hospital Anxiety and Depression Scale The HADSD is a self-assessment questionnaire measuring levels of anxiety and depression in patients. It contains two subscales: one for anxiety and one for depression. Total scores range from 0 to 42, with higher scores indicatiBAng higher levels of anxiety or depression. Baseline, after 3 and 6 months
Secondary EoD-Questionnaire: End of Dose-Questionnaire The EoD-Questionnaire assesses the effectiveness of a treatment at the end of its dosing interval and asks about an increase in symptoms. Baseline, after 3 and 6 months
Secondary Sleep-Questionnaire: The Sleep-Questionnaire contain the Pittsburgh Sleep Quality Index (PSQI) as well as two Items on the perceived impact of the smartwatch on the patient´s sleep. The PSQI assesses the quality of sleep over a one-month interval and measures seven component scores: sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleep medication, and daytime dysfunction. Total score ranges from 0 to 21, with higher scores indicating a poorer sleep quality. Baseline, after 3 and 6 months
Secondary 10. Questionnaire on Smartwatch Usage (after 6 Months) containing the System Usability Scale After 6 months
Secondary Digital Measurements: Activity parameters - Longitudinal development of step count 6 months, continuously
Secondary Digital Measurements: Activity parameters - longitudinal development of approximate distance travelled (meter) 6 months, continuously
Secondary Digital Measurements: Activity parameters - longitudinal development of duration of soft activity (seconds) as defined by Withings 6 months, continuously
Secondary Digital Measurements: Activity parameters - longitudinal development of duration of moderate activity (seconds) as defined by Withings 6 months, continuously
Secondary Digital Measurements: Activity parameters - longitudinal development of duration of itnense activity (seconds) as defined by Withings 6 months, continuously
Secondary Digital Measurements: Activity parameters - longitudinal development of active time (seconds) as defined by Withings 6 months, continuously
Secondary Digital Measurements: Activity parameters - longitudinal development of approximate calories burned as defined by Withings 6 months, continuously
Secondary Digital Measurements: Sleep parameters - longitudinal development of time awake (seconds) 6 months, continuously
Secondary Digital Measurements: Sleep parameters - longitudinal development of number of times user woke up 6 months, continuously
Secondary Digital Measurements: Sleep parameters - longitudinal development of time to sleep (seconds) 6 months, continuously
Secondary Digital Measurements: Sleep parameters - longitudinal development of total time asleep (seconds) 6 months, continuously
Secondary Digital Measurements: Sleep parameters - longitudinal development of total time in bed (seconds) 6 months, continuously
Secondary Digital Measurements: Sleep parameters - longitudinal development of ratio of sleep/time in bed 6 months, continuously
Secondary Digital Measurements: Sleep parameters - longitudinal development of time spent in bed before falling asleep (seconds) 6 months, continuously
Secondary Digital Measurements: Sleep parameters - longitudinal development of time awake after first falling asleep (seconds) 6 months, continuously
Secondary Digital Measurements: Sleep parameters - longitudinal development of Withings sleep Score as defined by Withings 6 months, continuously
Secondary Digital Measurements: Cardiovascular parameters - longitudinal development of average heartrate (beats/min) 6 months, continuously
Secondary Digital Measurements: Cardiovascular parameters - longitudinal development of maximal heartrate (beats/min) 6 months, continuously
Secondary Digital Measurements: Cardiovascular parameters - longitudinal development of minimum heartrate (beats/min) 6 months, continuously
Secondary Digital Measurements: Cardiovascular parameters - longitudinal development of time in light heartrate zone (seconds) 6 months, continuously
Secondary Digital Measurements: Cardiovascular parameters - longitudinal development of time in moderate heartrate zone (seconds) 6 months, continuously
Secondary Digital Measurements: Cardiovascular parameters - longitudinal development of time in intense heartrate zone (seconds) 6 months, continuously
Secondary Digital Measurements: Cardiovascular parameters - longitudinal development of time in maximal heartrate zone (seconds) 6 months, continuously
Secondary Digital Measurements: Cardiovascular parameters - longitudinal development of heart rate variability (milliseconds) 6 months, continuously
Secondary Smartwatch adherence Wearing time of smartwatch (daily) Continously 6 motnhs
See also
  Status Clinical Trial Phase
Completed NCT05039190 - Evaluate the Efficacy and Safety of HBM9161(HL161)Subcutaneous Injection in Patients With Generalized MG Patients Phase 3
Recruiting NCT04561557 - Safety and Efficacy of CT103A Cells for Relapsed/Refractory Antibody-associated Inflammatory Diseases of the Nervous System Early Phase 1
Completed NCT01727193 - The Efficacy and Safety of Leflunomide or Azathioprine Therapy in Myasthenia Gravis Patients After Expand Thymectomy Phase 3
Completed NCT00285350 - Mycophenolate Mofetil in Myasthenia Gravis Phase 3
Recruiting NCT05890833 - The Risk of Falls Index for Patients With Neuromuscular Disorders
Completed NCT05694234 - Influences of Sugammadex on Postoperative Progress in Patients With Myasthenia Gravis Undergoing Video-assisted Thoracoscopic Thymectomy: Retrospective Study
Recruiting NCT05635266 - Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives
Not yet recruiting NCT04965987 - Oxaloacetate in Myasthenia Gravis Phase 1
Not yet recruiting NCT05095103 - Immune Profiles in Myasthenia Gravis
Completed NCT02774239 - A Pilot Trial To Assess The Feasibility And Efficacy Of SCIG In Patients With MG Exacerbation (SCIG-MG) Phase 3
Terminated NCT02102594 - Therapy of Antibody-mediated Autoimmune Diseases by Bortezomib (TAVAB) Phase 2
Completed NCT02066519 - Benefits and Tolerance of Exercise in Patients With Generalized and Stabilized Myasthenia Gravis N/A
Completed NCT02118805 - Innovative Measures of Speech and Swallowing Dysfunction in Neurological Disorders
Terminated NCT01828294 - Subcutaneous Ig Maintenance Therapy for Myasthenia Gravis Phase 1
Terminated NCT00727194 - Safety and Efficacy Study of Eculizumab in Patients With Refractory Generalized Myasthenia Gravis Phase 2
Completed NCT04590716 - Help Build an A.I. Model to Predict Myasthenia Gravis Symptom Patterns and Flares
Recruiting NCT04837625 - Study of Myasthenic Crisis in China
Not yet recruiting NCT01469858 - Perception and Multisensory Integration in Neurological Patients Using fMRI N/A
Completed NCT05408702 - Exercise in Autoimmune Myasthenia Gravis and Myasthenic Syndromes
Completed NCT03205306 - Myasthenia Gravis and Psyche